Anti-Human IL-33 (Clone 390412)

Purified Recombinant Human IL-33 (Accession # O95760)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Immunohistochemistry on Frozen Sections: This antibody should give satisfactory staining results when used on frozen sections at a concentration of 8-25 µg/ml.

Mouse Anti-Human Interleukin-33 (IL-33) (Clone 390412) recognizes an epitope on Human IL-33. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

IL-33 is expressed by a wide variety of cell types, including fibroblasts, mast cells, dendritic cells, macrophages, osteoblasts, endothelial cells, and epithelial cells.

IL-33 is a 30 kD proinflammatory cytokine that belongs to the IL-1 superfamily. It signals inflammation in the body via the stimulation of macrophages, neutrophils, B cells, Th2 cells, eosinophils, basophils and mast cells. IL-33 is a ligand for IL33R (ST2), which is part of a cytokine receptor gene cluster that includes IL-1RI and IL-1RII. IL-33 binds ST2 and complexes with the IL-1R Accessory Protein (IL-1R-AcP) to form a functional signaling receptor complex facilitating the activation of NF-B and MAP kinase signaling pathways resulting in the production of type 2 cytokines from polarized Th2 cells. IL-33R can exist as a type I transmembrane glycoprotein or a soluble glycoprotein. The soluble IL-33R is thought to serve as a decoy receptor which competitively antagonizes the binding of IL-33 thereby reducing its biological effects. IL-33 has been linked with asthma, allergies, endometriosis, and hay fever. In addition, IL-33 resides in keratinocytes of the skin and is thought to trigger the itching associated with dermatitis when subjected to irritation or allergic conditions. Furthermore, in APP/PS1 mice, IL-33 has been shown to be effective in reversing the buildup and preventing the new formation of amyloid plaques that are characteristic of Alzheimer’s disease. However, the action of extracellular IL-33 is limited due to rapid oxidation that causes a molecular conformational change which prevents it from binding to the ST2 receptor.

1. Liew, FY. et al.(2007) Eur J. Immunol. 37: 2779
2. Jefferies, CA. et al.(2007) Sci. STKE. 390: 31